Pharmaceutical

Teva and Biolojic enter therapeutic antibody development deal

Teva Pharmaceutical has signed a licence agreement with Biolojic Design for the development of BD9 to treat atopic dermatitis and asthma.

Dec 16, 2023 - 18:00
Teva and Biolojic enter therapeutic antibody development deal
Teva Pharmaceutical has signed a licence agreement with Biolojic Design for the development of BD9 to treat atopic dermatitis and asthma.
Read the original article

Tags:

Previous Article

Reneo cuts 70% of staff following Phase III trial failure

Next Article

FDA approves US WorldMeds’s iwilfin for neuroblastoma

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Neuroscience startup Neumora files for IPO

STAT+: Neuroscience startup Neumora files for IPO

Aug 25, 2023

GSK concludes Aiolos Bio acquisition for $1.4bn

GSK concludes Aiolos Bio acquisition for $1.4bn

Feb 16, 2024

CRISPR is about to make history. Here’s the 5-minute rundown of what to expect

CRISPR is about to make history. Here’s the 5-minute ru...

Dec 9, 2023